continues

Zacks Small Cap Research – TELO Continues to Impress – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

“Unprecedented” decline in teen drug use continues, surprising experts – Go Health Pro

by
“Unprecedented” decline in teen drug use continues, surprising experts – Go Health Pro

A new era “Kids who were in eighth grade at the start of the pandemic will be graduating from high school this year, and this unique cohort has ushered in the lowest rates of substance use we’ve seen in decades,” Miech noted. For alcohol, use in the past 12 months among eighth graders was at … Read more

Zacks Small Cap Research – MIRA Continues to Post Outstanding Test Results – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company … Read more

Triple-I Blog | Prodigious growth continues for the excess and surplus market, but how long will it last? – Go Health Pro

by
Triple-I Blog | Prodigious growth continues for the excess and surplus market, but how long will it last? – Go Health Pro

The Excess and Surplus (E&S) market has grown for five consecutive years by double-digit percentage rates. While expansion appears to have slowed, ample growth could [DP1] continue if major trends persist, according to Triple-I’s latest issue brief, Excess and Surplus: State of the Risk. As reported by S&P Global Intelligence, total premiums for 2023 reached $86.47 … Read more

Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. $7.0 million financing accomplished. – Go Well being Professional

by
Zacks Small Cap Analysis – VNRX: Nu.Q Vet Check is now obtainable in 17 international locations. Value slicing continues in a plan to be money move impartial in 2025. Administration centered on signing licensing offers for Seize-PCR (human most cancers detection technique) and Nu.Q NET for sepsis. .0 million financing accomplished. – Go Well being Professional

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT OPERATIONAL UPDATES Administration is implementing a important value slicing program with the aim of making certain that Volition (NYSE:VNRX) is money move impartial in 2025. Value reductions taken throughout 1H 2024 resulted in a 15.9% decline in working bills. Value discount measures have … Read more

x